Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

Journal: JAMA oncology
Published Date: Jan 1, 2020

Abstract

IMPORTANCE: Diagnosing the site of origin for cancer is a pillar of disease classification that has directed clinical care for more than a century. Even in an era of precision oncologic practice, in which treatment is increasingly informed by the presence or absence of mutant genes responsible for cancer growth and progression, tumor origin remains a critical factor in tumor biologic characteristics and therapeutic sensitivity.

Authors

  • Alexander Penson
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Niedzica Camacho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Youyun Zheng
    Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Anna M Varghese
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hikmat Al-Ahmadie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pedram Razavi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sarat Chandarlapaty
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Christina E Vallejo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Efsevia Vakiani
    Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Teresa Gilewski
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jonathan E Rosenberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Maha Shady
    Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dana W Y Tsui
    Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dalicia N Reales
    Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Adam Abeshouse
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Aijazuddin Syed
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ahmet Zehir
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Nikolaus Schultz
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Marc Ladanyi
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • David B Solit
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • David M Hyman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Barry S Taylor
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Michael F Berger
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Keywords

External Resources

Popular Topics
Recent Journals